Schrödinger, Inc. filed a Form 8-K on November 4, 2026, announcing third-quarter 2026 financial results and issuing a correction to an American Society of Hematology abstract that incorrectly described the status of a combination study for its MALT1 inhibitor SGR-1505.

Key Highlights

  • Abstract correction: The American Society of Hematology published an abstract stating Schrödinger has an ongoing combination study of SGR-1505 in patients with relapsed/refractory B cell malignancies, which the company disclosed is inaccurate.
  • Study not initiated: According to the filing, the company "has in fact not initiated a combination study of SGR-1505 under its FDA-cleared protocol."
  • Strategic exploration: The company disclosed it "is exploring strategic opportunities to continue development of SGR-1505," as previously disclosed.
  • Q3 2026 results: Schrödinger issued a press release on November 4, 2026, announcing financial results for the third quarter ended September 30, 2026, furnished as Exhibit 99.1.
  • Exchange listing: Schrödinger common stock trades on NASDAQ:SDGR with a par value of $0.01 per share.
  • Signing officer: The filing was signed by Richie Jain, Executive Vice President and Chief Financial Officer.

Schrödinger Disputes ASH Abstract Language on SGR-1505 Development Status

On November 4, 2026, Schrödinger, Inc. filed a current report under Item 7.01 (Regulation FD Disclosure) to correct information published by the American Society of Hematology in an abstract reporting data from a Phase 1 study of SGR-1505, the company's MALT1 inhibitor. According to the filing, the abstract stated that the company has an ongoing combination study of SGR-1505 in patients with relapsed/refractory B cell malignancies. The company stated that this characterization is not accurate.

Schrödinger disclosed that it "has in fact not initiated a combination study of SGR-1505 under its FDA-cleared protocol." The company further noted, citing prior disclosures, that it "is exploring strategic opportunities to continue development of SGR-1505." The filing does not provide additional clinical data or timelines related to the program, and the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Separately, the same Form 8-K covers the company's announcement of its financial results for the third quarter ended September 30, 2026, under Item 2.02 (Results of Operations and Financial Condition). The press release containing those results was furnished as Exhibit 99.1. The filing notes that this information is also not deemed "filed" for Section 18 purposes. The filing contains forward-looking statements, which the company identifies as subject to risks and uncertainties detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on the same date.

What Was Disclosed

Schrödinger filed an 8-K on November 4, 2026, to correct an ASH abstract that inaccurately described an ongoing combination study of SGR-1505, clarifying the study has not been initiated under its FDA-cleared protocol, and to announce third-quarter 2026 financial results via a furnished press release.